melanoma

IGNYTE trial data show 83.5% of responders alive at three years; Replimune plans third BLA resubmission after two FDA rejections.

Two companion trials published in Nature Medicine show oral FMT capsules raised immunotherapy response rates to 80% in lung cancer and 75% in melanoma, while reducing toxic side effects in kidney cancer.

Five-year KEYNOTE-942 trial data show Moderna and Merck's individualized neoantigen mRNA vaccine maintains a 49% reduction in melanoma recurrence or death.